Skip to content
Open access · CC-BY via OpenAlex

Clinical and Imaging Characteristics of Parkinson's Disease with Negative Alpha‐Synuclein Seed Amplification Assay

Sarah M. Brooker, Jacopo Pasquini, Seung Ho Choi, David-Erick Lafontant, Seyed‐Mohammad Fereshtehnejad, Yashar Zeighami, Piergiorgio Grillo, Giulietta Maria Riboldi, Houman Azizi, Roqaie Moqadam, Un Jung Kang, Kelly Nicole Holohan Nudelman, Andrew D. Siderowf, Caroline M. Tanner, Thomas Francis Tropea

Movement Disorders · 2026 · ▲ 10 citations

Abstract

BACKGROUND: The cerebrospinal fluid alpha-synuclein seed amplification assay (CSFasynSAA) detects alpha-synuclein aggregation in over 90% of individuals with sporadic PD (sPD). However, the clinical characteristics of sPD with negative CSFasynSAA remain undefined. OBJECTIVES: Describe clinical and neuroimaging characteristics of CSFasynSAA-negative sPD individuals in the Parkinson's Progression Markers Initiative (PPMI). METHODS: We identified sPD PPMI participants with a negative CSFasynSAA (SAA-, n = 80) or positive CSFasynSAA (SAA+, n = 856) result at baseline. For comparative analysis between groups, we used a reduced dataset (n = 79 SAA- and n = 237 SAA+) propensity-score matched on age, sex, and time since clinical diagnosis. Clinical parameters, dopamine transporter-single photon emission computed tomography (DAT-SPECT), and magnetic resonance imaging (MRI) brain volumetrics were analyzed. RESULTS: The SAA- and matched SAA+ groups had similar motor performance on the Movement Disorder Society Unified Parkinson's Disease Rating Scale-Part III (MDS-UPDRS-III) and similar cognitive performance on the Montreal Cognitive Assessment (MoCA) at baseline. The proportion with severe hyposmia was 12% for SAA- versus 73% for SAA+ (P < 0.001). Per PPMI enrollment criteria all participants were classified as having an abnormal DAT-SPECT. There were no significant differences in median quantitative DAT-SPECT measures between groups. The SAA- group showed a higher degree of atrophy in subcortical brain regions including substantia nigra. Longitudinally, 14.3% of SAA- participants had a change in diagnosis versus 0.9% of SAA+ participants. CONCLUSIONS: At baseline, SAA- sPD PPMI participants have a substantially lower rate of hyposmia, but otherwise cannot be readily distinguished from SAA+ participants based on clinical characteristics. However, SAA- participants have a greater degree of subcortical brain atrophy, and approximately one out of seven SAA- participants received a change in diagnosis. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.1002/mds.70197
Canonical
link ↗
Fetched
2026-10-21 MST

Cite this

APA
Brooker, S.M., Pasquini, J., Choi, S.H., Lafontant, D., Fereshtehnejad, S., Zeighami, Y., Grillo, P., Riboldi, G.M., Azizi, H., Moqadam, R., Kang, U.J., Nudelman, K.N.H., Siderowf, A.D., Tanner, C.M., Tropea, T.F., Foroud, T., Chahine, L.M., Mollenhauer, B., Merchant, K., &amp; Galasko, D.R. (2026). Clinical and Imaging Characteristics of Parkinson's Disease with Negative Alpha‐Synuclein Seed Amplification Assay. <em>Movement Disorders</em>. https://doi.org/10.1002/mds.70197
Vancouver
Brooker SM, Pasquini J, Choi SH, Lafontant D, Fereshtehnejad S, Zeighami Y, et al. Clinical and Imaging Characteristics of Parkinson's Disease with Negative Alpha‐Synuclein Seed Amplification Assay. Movement Disorders. 2026. doi:10.1002/mds.70197.
BibTeX
@article{sarah2026Clinic, title = {Clinical and Imaging Characteristics of Parkinson's Disease with Negative Alpha‐Synuclein Seed Amplification Assay}, author = {Sarah M. Brooker and Jacopo Pasquini and Seung Ho Choi and David-Erick Lafontant and Seyed‐Mohammad Fereshtehnejad and Yashar Zeighami and Piergiorgio Grillo and Giulietta Maria Riboldi and Houman Azizi and Roqaie Moqadam and Un Jung Kang and Kelly Nicole Holohan Nudelman and Andrew D. Siderowf and Caroline M. Tanner and Thomas Francis Tropea and Tatiana Foroud and Lana M. Chahine and Brit Mollenhauer and Kalpana Merchant and Douglas R Galasko and Christopher S. Coffey and Roseanne D. Dobkin and Ethan G. Brown and Roy N. Alcalay and Daniel A. Weintraub}, journal = {Movement Disorders}, year = {2026}, doi = {10.1002/mds.70197}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings